Octave Announces Publication of Analytical Validation Study Results in Nature Communications More

Octave at the Consortium of Multiple Sclerosis Centers 2024 Annual Meeting

Wednesday, May 29 – Saturday, June 1
Nashville, TN

We are excited to engage with leading experts in MS at the 2024 CMSC Annual Meeting, where we’ll have the opportunity to present our innovative approach to revolutionizing care in MS and other neurodegenerative diseases.

Octave Supporter Showcase 2024

What’s Happening? Using a Multi-Protein Biomarker Test for Individualized Disease Activity Monitoring

Join us at the Octave Supporter Showcase to hear our collaborators discuss the science behind our precision care platform. 

Session Description

Personalized medicine is possible for your MS patients. This session presents the Octave Multiple Sclerosis Disease Activity (MSDA) Test, which provides validated, actionable insights into disease activity.

Explore crucial research and publications that demonstrate how this multi-protein biomarker approach enhances longitudinal patient management. 

Session Details

Meet our Panel

Taylor Gonyou, DO
Neurologist, Michigan Institute for Neurological Disorders Comprehensive MS Center
Julie Burnham, DO
President/Owner Michigan Neurology
Olaf Stuve, MD, PhD

Chief of Neurology, Dallas Veterans Affairs Medical Center,
Head of MS/Neuroimmunology section

Professor- Department of Neurology UT Southwestern Medical Center

Meet our Host

Jennifer Graves, MD, PhD, MAS

Professor of Neurosciences, UC San Diego

Vice Chair of Human Clinical Research, UC San Diego

Division Chief, Neuroimmunology, UC San Diego

Director, Rady Children’s Pediatric MS Center


Neuroinnovation Competition 2024

Octave's MSDA test continues to support clinical research at CMSC

We’re excited that the Octave MSDA Test results are being highlighted as part of Professor Ahmed Z. Obeidat’s Cytokind, Inc., sponsored poster that focuses on the Unmet Needs in MS. This poster is a finalist for the prestigious title of the 2024 Consortium of Multiple Sclerosis Centers’ “CMSC Neuroinnovator of the Year”. The 2024 CMSC Neuroinnovation Competition aims to recognize and celebrate original and innovative work in the field of MS research.

Presentation Description

Dr. Obeidat will present, Background, Advances, and Design of the Phase 2 Randomized Trial of @Home Phototherapy for MS, the “Silent Symptoms Trial,” the first phase 2 trial to bring the benefits of phototherapy for MS. It is a placebo-controlled trial that will be conducted within a real-world MS population.

Complementary And Alternative Therapies

Thursday, May 30, 2024: 5:00 PM – 7:00 PM, Exhibit Hall AB

Meet the Octave Team at CMSC

Chat with Our Team at the Octave Booth

Booth Details

  • Location: Booth 511
  • Hours:
    • Wednesday, May 29, 2024 (3:30pm – 8:00pm)
    • Thursday, May 30, 2024 (11:30am – 2:45pm & 4:30pm – 7:45pm)
    • Friday, May 31, 2024 (11:00am – 2:45pm)

Discover our science at the 2024 Poster Presentations

Comparing Neuroradiologist Qualitative Rating of Atrophy to Normative Brain Volume Measures

Discover how the comparison between the qualitative ratings of atrophy and normative brain volume measures can help us track MS disease progression more accurately.

We will present how the MOVING-MS study captured the clinical utility of the Octave platform, and it’s positive impact on patients’ clinical outcomes.  

Poster Presentation Details

  • Location: Exhibit Hall AB
  • Time: May 30, 2024 (5:00pm – 7:00pm)
Questions? Please reach out to [email protected]

Check out Octave at CMSC